中文名 | 6-甲基-1,1'-[2-(5-甲基-2-苯基-4-恶唑基)乙基]-螺[4H-3-1,1-苯并恶嗪-4,4'-哌啶]-2(1H)-酮 |
英文名 | 6-methyl-1'-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one |
别名 | 化合物RS 504393 6-甲基-1'-[2-(5-甲基-2-苯基-4-恶唑基)乙基]螺[4H-3,1-苯并恶嗪-4,4'-哌啶]-2(1H)-酮 6-甲基-1'-(2-(5-甲基-2-苯基恶唑-4-基)乙基)螺[苯并[D][1,3]恶嗪-4,4'-哌啶]-2(1H)-一 6-甲基-1'-(2-(5-甲基-2-苯基恶唑-4-基)乙基)螺[苯并[D][1,3]恶嗪-4,4'-哌啶]-2(1H)-酮 6-甲基-1'-[2-(5-甲基-2-苯基-噁唑-4-基)乙基]-螺[4H-3,1-苯并噁嗪-4,4'-哌啶]-2(1H)-酮 6-甲基-1,1'-[2-(5-甲基-2-苯基-4-恶唑基)乙基]-螺[4H-3-1,1-苯并恶嗪-4,4'-哌啶]-2(1H)-酮 6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮 6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮 1级 |
英文别名 | RS504393 RS 504393 RS-504393 6-Methyl-1'-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidi 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin] 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2( 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one 6-Methyl-1'-(2-(5-Methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one 6-Methyl-1'-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one 6-methyl-1'-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one Spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one, 6-Methyl-1'-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl]- Spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one, 6-methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- |
CAS | 300816-15-3 |
化学式 | C25H27N3O3 |
分子量 | 417.5 |
InChI | InChI=1/C25H27N3O3/c1-17-8-9-22-20(16-17)25(31-24(29)27-22)11-14-28(15-12-25)13-10-21-18(2)30-23(26-21)19-6-4-3-5-7-19/h3-9,16H,10-15H2,1-2H3,(H,27,29) |
密度 | 1.28 |
溶解度 | DMSO: 溶解1mg/mL,澄清 (温热) |
折射率 | 1.645 |
存储条件 | 2-8°C |
外观 | 粉末 |
颜色 | white to beige |
MDL号 | MFCD09038564 |
体外研究 | RS 504393 inhibits the MCP-1-induced chemotaxis with an IC 50 of 330 nM. RS 504393 treatment suppresses allergen induced β-hexosaminidase release significantly. Without allergen priming, MCP-1 induces mast cell degranulation, which is completely suppressed by RS 504393. |
体内研究 | RS504393 (0.3-3 μg) with CCL2 progressively blocks thermal hyperalgesia dose-dependently in mice. RS 504393 (5mg/kg, i.v.) supresses the elevated numbers of leukocytes and increased total protein content in BALF induced by The LPS. RS504393 significantly down regulates the LPS-induced elevation of IL-1β, PAI-1 mRNA and protein expressions. RS504393 significantly suppresses induced lung edema, protein-rich fluid, polymorphonuclear accumulation and bronchial wall thickening induced by LPS. RS-504393 significantly reduces renal pathology, especially the extensive interstitial fibrosis mediated by decrease in type I collagen synthesis in a UUO model. |
危险品标志 | Xi - 刺激性物品 |
风险术语 | 36/37/38 - 刺激眼睛、呼吸系统和皮肤。 |
安全术语 | 26 - 不慎与眼睛接触后,请立即用大量清水冲洗并征求医生意见。 |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.395 ml | 11.976 ml | 23.952 ml |
5 mM | 0.479 ml | 2.395 ml | 4.79 ml |
10 mM | 0.24 ml | 1.198 ml | 2.395 ml |
5 mM | 0.048 ml | 0.24 ml | 0.479 ml |